Company: MDCXW
Filing Date: 2025-03-07
Form Type: 253G1
Source: 0001062993-25-004966
Chunk: 67

Company: Medicus Pharma Ltd.
Filing Date: 2025-03-07
Form: 253G1
Chunk 67
---
 Canadian securities laws.

<div align='center'>- 40 -

DIVIDEND POLICY</div>

We do not anticipate that we will declare or pay dividends in the foreseeable future on our common shares. Instead, we anticipate that all of our earnings will be used for the operation and growth of our business. Any future determination to declare cash dividends would be subject to the discretion of our board of directors and would depend upon various factors, including our results of operations, financial condition and liquidity requirements, restrictions that may be imposed by applicable law and our contracts and other factors deemed relevant by our board of directors.

<div align='center'>- 41 -

CAPITALIZATION</div>

The following table sets forth our consolidated capitalization as of September 30, 2024:

| - | on an actual basis, as determined in accordance with IFRS; and                                                                                                                                                          |
| - | on an adjusted basis to reflect the net proceeds from our sale of 1,490,000 Units in this offering at the public offering price of $2.80 per Unit, after deducting the commissions and the estimated offering expenses. |

This table should be read in conjunction with the "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Use of Proceeds" sections, as well as our audited financial statements, included elsewhere in this offering circular.

|                            | As of September 30, 2024 |             |
|:---------------------------|-------------------------:|------------:|
|                            |                   Actual |    Adjusted |
| Cash and cash equivalents  |               $5,306,159 |  $8,415,259 |
| Liabilities                |                2,228,805 |   2,228,805 |
| Shareholders' equity:      |                          |             |
| Share capital              |               30,516,801 |  33,625,901 |
| Contributed surplus        |                  727,300 |     727,300 |
| Deficit                    |              -27,751,997 | -27,751,997 |
| Total shareholders' equity |                3,492,104 |   6,601,204 |
| Total capitalization       |               $5,720,909 |  $8,830,009 |

<div align='center'>- 42 -

USE OF PROCEEDS</div>

We estimate that the net proceeds to us from this offering will be approximately $3,109,100, based on a